Last reviewed · How we verify
Savolitinib + Osimertinib
Savolitinib and osimertinib together target MET and EGFR pathways to overcome resistance in lung cancer.
Savolitinib and osimertinib together target MET and EGFR pathways to overcome resistance in lung cancer. Used for EGFR-mutant non-small cell lung cancer (NSCLC) with MET alterations or at risk of MET-driven resistance.
At a glance
| Generic name | Savolitinib + Osimertinib |
|---|---|
| Sponsor | Hutchison Medipharma Limited |
| Drug class | Tyrosine kinase inhibitor combination |
| Target | EGFR and MET |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Savolitinib is a MET inhibitor that addresses MET-driven resistance to EGFR inhibitors, while osimertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR mutations. The combination is designed to prevent or overcome acquired resistance in EGFR-mutant non-small cell lung cancer by simultaneously blocking both EGFR and MET signaling pathways.
Approved indications
- EGFR-mutant non-small cell lung cancer (NSCLC) with MET alterations or at risk of MET-driven resistance
Common side effects
- Diarrhea
- Rash
- Nausea
- Vomiting
- Elevated liver enzymes
Key clinical trials
- A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (PHASE2)
- Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (PHASE2)
- AZD9291 in Combination With Ascending Doses of Novel Therapeutics (PHASE1)
- Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification (PHASE2)
- Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC (PHASE3)
- Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification (PHASE3)
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (PHASE2)
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Savolitinib + Osimertinib CI brief — competitive landscape report
- Savolitinib + Osimertinib updates RSS · CI watch RSS
- Hutchison Medipharma Limited portfolio CI